Gaurav K. Gupta - 01 Sep 2026 Form 3 Insider Report for Merck & Co., Inc. (MRK)

Reporting relationship: EVP, CIDO
Issuer ticker: MRK
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 01 Sep 2026, 15:40:40 UTC
Source filing: View source filing
Reporting owner signature: /s/ Kelly E. Grez, as Attorney-in-Fact for Gaurav Gupta

Key filing fact

Gaurav K. Gupta filed Form 3 for Merck & Co., Inc. (MRK) on 01 Sep 2026.

Key facts

This page summarizes Gaurav K. Gupta's Form 3 filing for Merck & Co., Inc. (MRK).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Sep 2026, 15:40.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002148939 Primary reporting owner

Gupta Gaurav K

Relationship: EVP, CIDO
Address: 126 EAST LINCOLN AVENUE, RAHWAY
Signature: /s/ Kelly E. Grez, as Attorney-in-Fact for Gaurav Gupta
Signature date: 01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 750
Date: 01 Sep 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRK holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,443
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 8/7/2027, 8/7/2028, and 8/7/2029.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

SEC remarks

See Exhibit 24 - Power of Attorney